• Avicanna posted Q2 revenue of $5.64 million, down 8% year over year on Veterans Affairs Canada reimbursement cuts.
• Gross margin climbed 6 percentage points to 57%, supported by a higher mix of proprietary products.
• Adjusted EBITDA loss widened to $0.36 million from $0.25 million a year earlier as the revenue drop outweighed cost efficiencies.
• Proprietary product units rose 33% year over year to 67,174, including 48% quarter-over-quarter growth.
• QUIX rapid-onset portfolio set for a Q3 launch with more than 35 commercial listings secured; management expects positive adjusted EBITDA in H2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avicanna Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608141830PRIMZONEFULLFEED9810712) on August 14, 2026, and is solely responsible for the information contained therein.